SUNNYVALE, Calif., March 28, 2018 /PRNewswire/ -- Personalized,
precise, radiation treatments will soon be available to more cancer
patients in India. Accuray
Incorporated (NASDAQ: ARAY) announced today that the company has
signed an agreement with the Apollo Hospitals Group in Chennai and New
Delhi, India, for the acquisition of two Radixact® Systems,
radiation therapy devices that have been proven to deliver highly
accurate treatments for a broad range of tumors anywhere in the
body. The installation of these systems, one replacing a
conventional linear accelerator and the other in a new vault, will
expand access to state-of-the-art cancer treatment technology for
the people of India. The orders
were entered into backlog during Accuray Incorporated's Q3 fiscal
quarter, which ends March 31,
2018.
Apollo Hospitals was established in 1983 and has since emerged
as Asia's foremost integrated
healthcare services provider. This patient-centric organization's
mission is to bring the highest standards of healthcare to every
patient.
Dr. Prathap C. Reddy, Chairman,
Apollo Hospitals Group said, "Cancer care requires passionate
commitment, cutting edge expertise along with unswerving dedication
to keep raising the bar and at Apollo we have embraced this ethos,
as our singular goal is to make cancer conquerable!"
Dr. Reddy added, "For over twenty–five years, Apollo Cancer
Centres have been serving patients from over 140 countries. Our
fine teams of Oncologists persevere relentlessly to offer patients
the global best in cancer care and a contemporary product such as
the Radixact System will help our patients by minimizing the impact
on their quality of life."
Radixact System Benefits
- The platform features a more powerful linear accelerator than
prior generations, as well as integrated 3D CTrue™ imaging and
helical treatment delivery, which enable physicians to deliver very
accurate, individualized dose distributions that precisely conform
to the shape of the patient's tumor while minimizing dose to
normal, healthy tissue, resulting in fewer side effects for
patients
- Daily 3D image guidance, which facilitates proper patient
positioning and dose targeting even when anatomical changes occur,
helps ensure treatment accuracy is achieved. Clinicians are able to
easily see the patient anatomy every day as part of the streamlined
delivery workflow, so that they know exactly where the tumor is on
that particular day
- The treatments are both highly efficient and effective,
expanding the reach of radiation therapy and enabling previously
untreatable cases to be treated with ease – and with a seamless
process
- Adaptive therapy, using PreciseART™ Adaptive Radiation Therapy
software, is highly automated and efficient, enabling the clinical
team to routinely incorporate adjustments to the treatment planning
and delivery process based on changes in tumor size, shape and
location — as well as subtle changes in the location of organs and
other healthy tissue
"We are honored to be partnering with Apollo Hospitals to
improve the lives of people with cancer. Our employees are focused
on a common goal – to put patients first by providing them with the
best possible care," said Lionel Hadjadjeba, M.D., Senior Vice
President, and Chief Commercial Officer at Accuray. "The Radixact®
System can be used to treat virtually any tumor type including
breast, head and neck, lung and prostate cancers, during every
stage of the treatment journey, from primary cases, to recurrent
and metastatic diseases. This gives the Apollo Hospitals clinical
team tremendous flexibility and enables them to tailor treatments
to the specific needs of each patient."
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement
About Apollo Hospitals Group
Apollo Hospitals was established in 1983 by Dr. Prathap C. Reddy. It was India's first corporate hospital, and is
acclaimed for pioneering the private healthcare revolution in the
country. Since then, Apollo has risen to a position of leadership
and has emerged as Asia's foremost
integrated healthcare services provider. It has a robust presence
across the healthcare ecosystem, including Hospitals, Pharmacies,
Primary Care & Diagnostic Clinics.
In a rare honour, the Government of India issued a commemorative stamp in
recognition of Apollo's widespread contributions, the first for a
healthcare organization. Dr. Prathap C.
Reddy, Founder Chairman of the Apollo Hospitals Group has
been conferred with the prestigious Padma Vibhushan, India's second highest civilian award. For
more information, please visit www.apollohospitals.com or follow us
on Facebook, Twitter, Blog, YouTube, LinkedIn, SlideShare and
Instagram
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and Accuray's
ability to continue to penetrate the global radiation therapy
market. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, the company's ability to develop new products or enhance
existing products to meet customers' needs, the company's ability
to anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's annual report on Form 10-K, filed with the Securities and
Exchange Commission (the "SEC") on August
25, 2017, the company's quarterly report on Form 10-Q, filed
with the SEC on February 5, 2018 and
as updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts
|
|
Beth
Kaplan
|
Marisa
Borgasano
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-0770
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/apollo-hospitals-in-india-to-acquire-two-accuray-radixact-systems-300620684.html
SOURCE Accuray Incorporated